Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Raised to $275.00 at Raymond James

Alnylam Pharmaceuticals (NASDAQ:ALNY) had its price objective hoisted by Raymond James from $242.00 to $275.00 in a report released on Friday, Benzinga reports. The firm currently has an outperform rating on the biopharmaceutical company’s stock.

A number of other analysts have also recently commented on ALNY. Chardan Capital reaffirmed a buy rating and set a $225.00 price target on shares of Alnylam Pharmaceuticals in a research report on Friday, May 3rd. BMO Capital Markets reaffirmed an outperform rating and set a $234.00 price target on shares of Alnylam Pharmaceuticals in a research report on Monday, June 24th. StockNews.com raised shares of Alnylam Pharmaceuticals from a hold rating to a buy rating in a research report on Monday, April 29th. Bank of America increased their price objective on shares of Alnylam Pharmaceuticals from $248.00 to $295.00 and gave the stock a buy rating in a research report on Tuesday, June 25th. Finally, HC Wainwright reissued a buy rating and set a $400.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Monday, June 24th. Eight equities research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of Moderate Buy and an average price target of $269.32.

Alnylam Pharmaceuticals Stock Down 2.6 %

NASDAQ ALNY opened at $265.00 on Friday. The company has a market capitalization of $33.52 billion, a price-to-earnings ratio of -98.88 and a beta of 0.37. Alnylam Pharmaceuticals has a twelve month low of $141.98 and a twelve month high of $274.93. The stock has a fifty day simple moving average of $211.34 and a 200 day simple moving average of $175.01.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported ($0.13) EPS for the quarter, beating analysts’ consensus estimates of ($0.74) by $0.61. The firm had revenue of $659.83 million for the quarter, compared to the consensus estimate of $447.22 million. The business’s revenue was up 107.0% compared to the same quarter last year. During the same period last year, the company posted ($2.21) EPS. Research analysts expect that Alnylam Pharmaceuticals will post -3.99 earnings per share for the current fiscal year.

Insider Transactions at Alnylam Pharmaceuticals

In other news, Director Amy W. Schulman sold 21,700 shares of the firm’s stock in a transaction that occurred on Wednesday, May 29th. The shares were sold at an average price of $148.60, for a total transaction of $3,224,620.00. Following the completion of the sale, the director now owns 8,436 shares in the company, valued at approximately $1,253,589.60. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In related news, Director David E. I. Pyott sold 32,450 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Monday, June 24th. The shares were sold at an average price of $220.69, for a total value of $7,161,390.50. Following the completion of the transaction, the director now directly owns 136 shares in the company, valued at approximately $30,013.84. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Amy W. Schulman sold 21,700 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Wednesday, May 29th. The shares were sold at an average price of $148.60, for a total transaction of $3,224,620.00. Following the completion of the transaction, the director now owns 8,436 shares of the company’s stock, valued at $1,253,589.60. The disclosure for this sale can be found here. Insiders sold a total of 89,598 shares of company stock worth $19,377,944 in the last quarter. Insiders own 1.50% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the company. ANTIPODES PARTNERS Ltd grew its position in Alnylam Pharmaceuticals by 69.1% in the fourth quarter. ANTIPODES PARTNERS Ltd now owns 189,141 shares of the biopharmaceutical company’s stock worth $36,203,000 after acquiring an additional 77,307 shares in the last quarter. Vanguard Group Inc. boosted its position in Alnylam Pharmaceuticals by 2.5% during the fourth quarter. Vanguard Group Inc. now owns 11,943,895 shares of the biopharmaceutical company’s stock valued at $2,286,181,000 after buying an additional 287,064 shares during the period. Robeco Institutional Asset Management B.V. boosted its position in Alnylam Pharmaceuticals by 155.7% during the fourth quarter. Robeco Institutional Asset Management B.V. now owns 20,549 shares of the biopharmaceutical company’s stock valued at $39,000 after buying an additional 12,513 shares during the period. Quattro Financial Advisors LLC boosted its position in Alnylam Pharmaceuticals by 2,517.8% during the first quarter. Quattro Financial Advisors LLC now owns 5,000 shares of the biopharmaceutical company’s stock valued at $747,000 after buying an additional 4,809 shares during the period. Finally, Westpac Banking Corp boosted its position in Alnylam Pharmaceuticals by 59.8% during the fourth quarter. Westpac Banking Corp now owns 1,512 shares of the biopharmaceutical company’s stock valued at $289,000 after buying an additional 566 shares during the period. 92.97% of the stock is currently owned by hedge funds and other institutional investors.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.